Liting Xue

机构：China Pharmaceutical University, Shanxi Medical University, Shanxi University, Simcere Pharmaceutical (China), Fosun Pharma (China), Shanxi Provincial People’s Hospital · ORCID：0000-0002-5277-4433

发表论文 67 篇 · 总被引 564 次 · h-index 9

代表论文

• SCR‐7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S ‐adenosylmethionine‐competitive or the methylthioadenosine‐cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase‐deleted tumors (2024 · MedComm · 被引 10)
• High intratumoral heterogeneity in clear cell renal cell carcinoma is associated with reduced immune response and survival (2025 · Translational Andrology and Urology · 被引 6)
• Abstract LB271: Synergistic anti-tumor efficacy in olaparib-sensitive and -resistant models via simultaneously inhibition of USP1 and PARP (2024 · Cancer Research · 被引 5)
• Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy (2025 · Journal of Medicinal Chemistry · 被引 3)
• Technical considerations and strategies for generating and optimizing humanized mouse tumor models in immuno-oncology research (2024 · International Immunopharmacology · 被引 2)
• Abstract PS15-01: A first-in-human phase 1 study of SIM0270, a brain-penetrant oral selective estrogen receptor degrader (SERD), in patients with ER+/HER2- locally advanced or metastatic breast cancer (2024 · Cancer Research · 被引 2)